A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Genprex, Inc.
Daiichi Sankyo
Centre Francois Baclesse
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
New Mexico Cancer Research Alliance
Chroma Therapeutics
Clinical Research Center for Solid Tumor, Korea